Background and objectives Antiglomerular basement membrane autoantibodies are pathogenic in antiglomerular basement membrane disease with two major epitopes, E A and E B , on a3 chain of type IV collagen. This study investigated the epitope spectrum of antiglomerular basement membrane autoantibodies, aiming to identify the association between epitope specificity and kidney injury.
Introduction
Antiglomerular basement membrane (anti-GBM) disease, also termed Goodpasture's disease, is a rare autoimmune disorder characterized by rapidly progressive glomerulonephritis and high risk of pulmonary hemorrhage (1) . Anti-GBM autoantibody has been shown as a pathogenic factor to disease initiation (2), with the major target antigen located on the noncollagenous domain of a3 chain of type IV collagen [a3(IV)NC1] on GBM (3) (4) (5) . Two conformational epitopes have been discovered: residues 17-31 are named E A , and residues 127-141 are named E B (6) (7) (8) (9) . However, the role of epitope specificity and its variation are less clear in the initiation and progression of human anti-GBM disease.
Epitope spreading is defined as the development of immune responses to epitopes distinct from and noncrossreactive with the original epitope, which initiates the immune response (10) . Epitope spreading within the same molecule (intramolecular) or to the other molecules (intermolecular) has been documented in many autoimmune disorders (11) (12) (13) . The spread of autoimmunity amplifies the deleterious process of tissue injury, and the consequence is vice versa (14) . Both intra-and intermolecular epitope spreading were shown in animal models of anti-GBM disease (15, 16) . We recently provided evidence that intermolecular epitope spreading may occur in human anti-GBM disease (17) .
In the current study, epitope specificity of anti-GBM antibodies was determined using recombinant E A , E B , and non-E AB [the region of a3(IV)NC1 apart from E A and E B ] in a large cohort of patients with different kidney injury and sequential serum samples. Clinical and pathologic features were also investigated, aiming to find the association between epitope specificity and severity of kidney injury and the possible intramolecular epitope spreading in disease initiation.
Materials and Methods

Sera and Patients
Sera from 108 patients with anti-GBM disease, diagnosed in Peking University First Hospital during 1997-2008, were collected on diagnosis before immunosuppressive treatment or plasmapheresis. Serial serum samples collected during disease courses were available in 40 patients. All the sera were positive for anti-GBM autoantibodies by ELISA using purified bovine a(IV)NC1 and recombinant human a3(IV)NC1 as solid-phase antigens. All the sera were negative for antineutrophil cytoplasmic antibody by indirect immunofluorescence using ethanol-fixed human neutrophils and antigen-specific ELISA against purified myeloperoxidase and proteinase 3. Sera from 50 healthy blood donors were used as normal controls. All the sera were stored at 220°C until use.
Clinical and pathologic data were collected from medical records at the time of presentation and during follow-up visits. Renal biopsies were performed in 82 patients with linear deposition of IgG with or without C3 along GBM by immunofluorescence. Crescentic glomerulonephritis was defined as a large crescent (.50%) formation involving in over 50% of glomeruli. Informed consent was obtained for each sampling of tissue and blood. The research was in compliance with the Declaration of Helsinki and approved by the ethics committee of our hospital.
Preparation of Recombinant Human E A , E B , and non-E AB
Recombinant proteins were produced as described earlier (6, 18) . Briefly, cDNA from the NC1 domain of human type IV collagen a1 and a3 was ligated to a type X collagen triple helix leader sequence and subcloned into pcDNA3 vector, respectively. The constructs were then stably transfected into a human embryonic kidney cell line (HEK 293). Recombinant proteins were harvested and purified from the medium by affinity chromatography, and they were designated as recombinant a1 and a3. Chimeric constructs containing different combinations of sequences from a1(IV) and a3(IV) were produced by the extension PCR technique. E A consisted entirely of a1(IV)NC1 domain, with 45 amino acids of a3(IV)NC1 containing the Hudson E A site (8) . E B consisted entirely of a1(IV)NC1, with 37 amino acids of a3(IV)NC1 containing the Hudson E B site (8) . Non-E AB consisted entirely of a3(IV)NC1, with the region of E A and E B substituted by a1(IV)NC1.
Detection for Antibodies against E A , E B , and Non-E AB by ELISA The recombinant human E A , E B , and non-E AB were diluted 2 mg/ml with 50 mEq/L bicarbonate buffer (pH 9.6) and coated onto three-quarters of the wells of a polystyrene microtitre plate (Nunc; Roskiled, Denmark). The other one-quarter of the wells were coated with 50 mEq/L bicarbonate buffer as antigen-free wells to exclude nonspecific binding. Incubation was performed at 37°C for 60 minutes. Test sera were diluted 1:50 in PBS containing 0.1% Tween-20 (PBST) and added to both antigen-coated and -free wells at 37°C for 30 minutes. Then, alkaline phosphatase-conjugated goat anti-human IgG (Fc-specific; Sigma, St. Louis, MO) diluted 1:4000 was added at 37°C for 30 minutes. P-nitrophenyl phosphate (100 mg/dl; Sigma, St. Louis) in substrate buffer (105 g/L diethanolamine, 4.8 mg/dl MgCl 2 , pH 9.8) was used as substrate, and color development was measured spectrophotometrically at 405 nm (Bio-Rad, Tokyo, Japan). The plates were washed three times between steps, and the volume of each well was 100 ml. Each plate contained positive, negative, and blank (PBST) controls. Sera from a patient with predetermined high titers of autoantibodies against E A , E B , and non-E AB were used as positive controls. When standard errors over 10% were found, samples were re-examined. Absorbance values from antibicarbonate ELISA were subtracted from the results of anti-E A , E B , and non-E AB ELISAs. Sera from 50 normal individuals diluted 1:50 were used to build up the cutoff values using mean + 2 SD.
Statistical Analyses
Differences of quantitative parameters were assessed using t tests or one-way ANOVAs. Differences of qualitative data were compared using chi-squared tests. Pearson or Spearman rank correlation was performed to analyze the relationship between the levels of antibodies against epitopes and the quantitative clinical parameters. KaplanMeier curves were used to analyze renal survival and patient survival. Univariate survival analyses were performed using log-rank tests. Multivariate survival analyses were performed using Cox regression models. Covariables were selected using the variables that showed a prognostic role in the previous univariate survival analysis. Results were expressed as hazard ratio (HR) with 95% confidence intervals (95% CIs). A P value,0.05 was considered significant. All statistical analyses were performed using PASW Statistics 18.0 (SPSS Inc., Chicago, IL).
Results
Demographic and Clinical Data
Among the 108 patients, 75 patients were male, and 33 patients were female. The mean age was 38.4617.3 years (15-89 years), and 40 (37.0%) patients had hemoptysis. The mean concentration of serum creatinine (Scr) on diagnosis was 8.265.2 mg/dl. The mean level of circulating anti-GBM autoantibodies was 68.1639.8 U/ml. Sixty-seven (81.7%) patients presented with crescentic glomerulonephritis. Fifty (61.0%) patients had crescents in more than 85% of the glomeruli.
The patients were divided into three groups according to the Scr on diagnosis. Group A (mild kidney dysfunction) included 20 patients with Scr#1.5 mg/dl; group B (moderate kidney dysfunction) included 22 patients with Scr=1.5-6.8 mg/dl, and group C (severe kidney dysfunction) included 66 patients with Scr$6.8 mg/dl.
The demographic, clinical, and pathologic data of patients in the three groups are shown in Table 1 . Patients in group C had a significantly higher proportion of oliguria/ anuria (P,0.001) and gross hematuria (P,0.001), higher Scr on diagnosis (P,0.001), higher level of anti-GBM autoantibodies (P,0.001), more crescents in glomeruli (P,0.001), and worse renal survival (P,0.001) than patients in groups A and B as expected.
Epitope Specificity of Anti-GBM Autoantibodies in Patients with Different Kidney Functions
The cutoff values of each epitope-specific ELISA were 0.043 for E A , 0.074 for E B , and 0.034 for non-E AB .
All sera from the 108 patients could recognize a3(IV) NC1, among which 86 (79.6%), 78 (72.2%), and 12 (11.1%) sera recognized E A , E B , and non-E AB, respectively ( Table 2 ). In group A (mild kidney dysfunction), the frequencies of sera recognizing E A and E B were 35.0% (7/20) and 15.0% (3/20), respectively. In group B (moderate kidney dysfunction), the frequencies of E A and E B recognition were significantly greater at 81.8% (18/22; P=0.002) and 68.2% (15/22; P=0.001). In group C (severe kidney dysfunction), the frequencies were greater at 92.4% (61/ 66; P=0.31) and 90.9% (60/66; P=0.02). Therefore, following the severity of impaired kidney function from group A to group C, the recognition of E A and E B was greater accordingly, with the difference being statistically significant for both E A and E B (P,0.001) (Figure 1 ).
Association between Epitope Specificity and Clinical Manifestations
Patients recognizing E A presented with higher levels of anti-GBM antibodies (72.7640.2 versus 51.3634.4 U/ml, P=0.03), higher Scr on diagnosis (9.364.8 versus 4.164.8 mg/dl, P,0.001), and higher frequencies of crescentic glomerulonephritis (88.2% versus 50.0%, P=0.003) than patients not recognizing E A . Patients recognizing E B presented with not only the same clinical features as the patients with anti-E A antibodies but also, a significantly higher proportion of oliguria/anuria (50.0% versus 13.3%, P,0.001) and a higher percentage of crescents in glomeruli (83.4625.8% versus 53.3640.2%, P=0.002) than patients with negative anti-E B antibodies ( Table 3) .
The prognostic significance of E A and E B reaction was determined by Kaplan-Meier curves and log-rank tests for univariate survival analyses to assess renal and patient outcomes. We found that the recognition for both E A (HR=4.10, 95% CI=1.77-9.50, P=0.001) and E B (HR=4.63, 95% CI=2.20-9.71, P,0.001) (Figure 2 ) and the reaction to both E A and E B (HR=3.74, 95% CI=1.96-7.16, P,0.001) were predictors for renal failure during follow-up visits. Furthermore, multivariate Cox regression analyses showed that the recognition for E B (HR=6.91, 95% CI=1.38-34.65, P=0.02) was an independent risk factor for renal failure ( Table 4 ). The recognition for neither E A nor E B was a predictor for patient death (P.0.05).
The recognition for non-E AB had no significant association with the clinical or pathologic data of patients (P.0.05).
Antibody Levels of Epitopes and Their Associations with Clinical Manifestations
The levels of antibodies against E A and E B both exhibited a greater tendency from group A to C, but no significant difference was found among the groups (P.0.05) ( Table 2 ). The levels of antibodies against non-E AB remained low in each group (P.0.05). None of the clinical manifestations were revealed to have correlations with the levels of antibodies against E A , E B , or non-E AB (P.0.05).
Epitope Spectrum of Anti-GBM Antibodies in Disease Courses with Serial Serum Samples
Anti-GBM autoantibodies against E A , E B , and non-E AB were detected in 40 patients (7 patients from group A, 14 patients from group B, and 19 patients from group C) with sequential serum samples during disease courses with Epitope specificity of anti-GBM autoantibodies was detected in these sequential serum samples. The frequencies of sera recognizing E A , E B , and non-E AB were all slightly decreased with time. No augmentation of epitope spectrum was observed on anti-GBM antibodies during disease courses (Figure 3) .
Discussion
In the current study, it was shown that both E A and E B were major epitopes for anti-GBM antibodies with high frequency of recognition; for E A , it was 79.6%, and for E B , it was 72.2%. It is consistent with previous reports (5, 8, 9, (18) (19) (20) . Difference in epitope specificity showed up when the patients were divided into three groups according to their renal functions at presentation. Among the three groups, the recognition for E A and E B became greater gradually from patients with normal kidney function (group A) to patients with moderate and severe renal Patients with serum creatinine#1.5 mg/dl were defined as group A (mild renal dysfunction); patients with serum creatinine=1.5-6.8 mg/dl were defined as group B (moderate renal dysfunction), and patients with serum creatinine$6.8 mg/dl were defined as group C (severe renal dysfunction). The frequencies of sera against E A and E B exhibited an increasing tendency from group A to group C. *P,0.05; **P,0.01. dysfunction (groups B and C). This difference reached significance among groups and was notable for epitope E B . This finding suggests that the epitope spectrums of anti-GBM antibodies might become broader gradually as renal function gets worse. In patients with different renal functions at different stages of disease progression, our findings provide the first evidence of intramolecular epitope spreading occurring in the development of human anti-GBM disease. Epitope spreading of B cells has been proven in the work by Bolton et al. (15) in an animal model; sera and kidney elute from rats immunized by a synthetic peptide of rat a3 (IV)NC1 reveal reactivity to not only the immunizing peptide but also, epitopes of a3(IV)NC1 external to the peptide immunogen. Another study indicates that a single T cell epitope of a3(IV)NC1 is sufficient to initiate the full clinical spectrum of anti-GBM disease, and it could also elicit antibody responses to diverse native GBM proteins (21) . In human anti-GBM disease, this study and our previous study (17) both provide evidence for epitope spreading occurring in disease development. Delineation of epitope spreading is essential to understanding the pathogenesis of autoimmune disease and developing potential therapies. For example, immune tolerance may be prompted through oral or nasal administration of appropriate epitopes, especially the original one, which initiates epitope spreading. Actually, it has been successful in animal experiments (22) . Help from T cells is required for epitope spreading of antibody response. The emergence, persistence, and disappearance of antibodies are all regulated by T and B cell crosstalks (23, 24) . In the absence of anti-GBM antibodies, a3(IV)NC1-specific CD4+ T cell alone is sufficient to initiate glomerular injury (25) . Thus, additional investigations on autoreactive T cells are needed in human anti-GBM disease. The pathogenic role of E A has been identified by the predominance of E A reaction in the total immunoreactivity of a3(IV)NC1 with high titer and affinity (9) . In rats, E A could induce florid disease similar to full-length native GBM (18) . The current study showed that patients with positive anti-E A antibodies had more severe kidney injury, which provides more evidence for the important role of E A in human anti-GBM disease.
The role of E B epitope in the pathogenesis is still controversial. Animal experiments showed that E B alone could not induce the disease; a half-dose each E A plus E B induced disease identical to E A alone. It suggests a nonpathogenic but augmenting effect of E B (18) . In this study, we found that patients with anti-E B antibodies presented with similar clinical features to patients with E A reaction, with higher antibody levels, higher serum creatinine, and more glomerular crescents. It implies a possible nephritogenic role of E B reaction in human anti-GBM disease. Furthermore, by multivariate Cox regression analysis, we identified that E B specificity, but not E A , was the independent prognostic factor for renal failure. These findings imply that a major pathogenic epitope may be located in E B .
E B is sequestered within the a3a4a5 protomer at the interface between the a3NC1 and a4NC1 domains (9, 18, 26, 27) . The binding of antibodies to E B would dissociate the interactions of a3NC1 and a4NC1, increase the accessibility of autoantibodies to these monomers, and subsequently, expand the immunogenicity of GBM antigens (26) . This mechanism gives an explanation for the probable pathogenic role of E B , and furthermore, it provides a bridge linking intra-and intermolecular epitope spreading that was revealed in human anti-GBM disease. We previously documented that a4(IV)NC1 was more frequently recognized as renal dysfunction deterioration (17) . During disease development, the expanding recognition for E B may lead to the dissociation of a3a4a5 protomer and the immunogenicity of a4NC1, hereby developing intermolecular epitope spreading to a4(IV)NC1. These findings suggest the need for additional studies about the potential clinical use of E B -specific immunity.
After disease presentation, we did not observe additional augmentation on the epitope spectrum of anti-GBM antibodies, which suggests that epitope spreading occurs before disease onset. Very similar observations have been reported in systemic lupus erythematosus and rheumatoid arthritis (28, 29) , where the accrual of new types of autoantibodies gradually increased up to the time of diagnosis and then virtually stopped. A possible explanation for this finding is the effects of immunosuppressive treatments, which are commonly prescribed after diagnosis is established.
In our patient group, 11.1% of patients had antibodies against non-E AB , which is in agreement with previous studies (9, 18) . However, their low frequency, low level, and lack of correlation with clinical features suggest a dispensable role in the disease.
The limitation of our study is that we used patients with different degrees of renal dysfunction to represent the progression of disease. It is not the real natural history of disease and makes our findings indirect evidence for the occurrence of epitope spreading. However, because of ethical considerations, it is impossible to perform experiments in human beings, like animal models, to investigate disease courses. Thus, we enrolled as many patients as we could with different clinical phenotypes to make the findings more credible.
In summary, we provide evidence that intramolecular epitope spreading may occur before the onset of human anti-GBM disease. The recognition of E A and the recognition of E B are both essential to disease initiation, especially the autoimmunity to E B , which is associated with the severity and prognosis of kidney impairment and may play a crucial role in antigen exposure and immune expansion.
